The strategy

Our own platform technologies, developed in-house, form the basis for innovative drugs that are clinically developed in line with state-of-the-art molecular medicine and immunology findings.

Our product pipeline is geared towards medical need and the products' market potential. The focus of our development work is on MOLOGEN`s proprietary platform technology: the product family of DNA-based TLR9 agonists. This includes our lead product, the immunotherapeutic agent lefitolimod, and its follow-up molecules EnanDIM®. Our product development helps combat some of the most threatening diseases.

The field of oncology is the main focus of our activities. As a result of demographic change in industrialized nations and the advancing development in emerging countries, this field will also be one of the future's strongest-selling classes of therapy. Furthermore, we develop immunotherapies for the treatment of infectious diseases. 

Within the framework of the `Next Level` strategy program, the biopharmaceutical company MOLOGEN, focuses on closer-to-the-market, proprietary product candidates which have advanced beyond the basic research-stage. Our foremost objective is the successful out-licensing and marketing of our products, particularly our lead product, the immunotherapeutic agent, lefitolimod.

In light of the strong medical demand and their excellent tolerability, our product candidates have tremendous sales potential. Our goal is to utilize this potential in collaboration with expert partners.